Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 3/20 | 0.44 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | UCHL3 | P15374 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25204837 | 0.82 | MAP4K4 (0.47) | MAP4K4TRPV3PDE10AKDM4EMAPT | |
| SCHEMBL21500109 | 0.82 | MAP4K4 (0.55) | MAP4K4HRH3HTR3AROCK2UCHL3 | |
| SCHEMBL25191131 | 0.80 | MAP4K4 (0.48) | MAP4K4TRPV3PDE10AKDM4EMAPT | |
| SCHEMBL22475332 | 0.80 | MAP4K4 (0.45) | MAP4K4PDE10AHRH3HTR3AROCK2 | |
| SCHEMBL2412222 | 0.79 | CNR2 (0.43) | MAP4K4HTR3AUCHL3 | |
| Hydrochloric Acid SCHEMBL6346443 | 0.78 | CNR2 (0.43) | MAP4K4HTR3AUCHL3 | |
| SCHEMBL2415579 | 0.78 | CNR2 (0.46) | MAP4K4MAPTHTR3A | |
| SCHEMBL2414036 | 0.78 | HRH4 (0.47) | MAP4K4PDE10AHRH3 | |
| SCHEMBL16931347 | 0.77 | HTR3A (0.57) | MAP4K4KDM4EHRH3HTR3AUCHL3 | |
| Hydrochloric Acid SCHEMBL2420468 | 0.77 | CNR2 (0.45) | MAP4K4MAPTHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327393-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-10-03 | — | — | US | disclosed |
| CN-117999259-A | Iron death modulators, their preparation and use | 维泰瑞隆有限公司 | 2024-05-07 | — | — | CN | disclosed |
| WO-2023280296-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327393-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | AIFM2, GPX1, GPX4 | MAP4K4 2878/4885TRPV3 2737/4885PDE10A 3241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.